Podcasts about ons

Deze week geen gast, maar een ijzersterke basis met Tim, Snijboon, Gijs en RogierPablo! Deze vier professionele amateurs bespreken met elkaar speelronde 08. ✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delen waar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

“I think that this is an area that is exploding. Working with drug development, I see new agents all the time, with unique targets I've never heard about, with targets I have heard about used in a different way. So, I really think we're going to see more and more bispecifics. A lot of these drugs are used second line, third line, fourth line. I would not be surprised if they moved up in treatment, especially as we learn safer ways to give these drugs,” ONS member Moe Schwartz, PharmD, BCOP, FHOP, professor of pharmacy practice at the James L. Winkle College of Pharmacy at the University of Cincinnati, OH, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about bispecific antibodies.  Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by October 3, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the use of bispecific antibodies in the treatment of cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 275: Bispecific Monoclonal Antibodies in Hematologic Cancers and Solid Tumors Episode 261: CAR T-Cell Therapy for Hematologic Malignancies Requires Education and Navigation Episode 176: Oncologic Emergencies: Cytokine Release Syndrome ONS Voice articles: An Oncology Nurse's Guide to Bispecific Antibodies Bispecific Antibodies Cross-Discipline Cancer Care ONS Voice oncology drug reference sheets: Amivantamab-Vmjw Blinatumomab Epcoritamab-Bysp Glofitamab-Gxbm Mosunetuzumab-Axgb Tebentafusp-Tebn Teclistamab-Cqyv ONS book: Guide to Cancer Immunotherapy (second edition) ONS course: ONS/ONCC® Chemotherapy Immunotherapy Certificate™ Clinical Journal of Oncology Nursing article: Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles Other ONS resources: Bispecific Antibodies Video Bispecifics Huddle Card Cytokine Release Syndrome Huddle Card Immune Effector Cell–Associated Neurotoxicity Syndrome Huddle Card DailyMed homepage Hematology/Oncology Pharmacy Association late-breaking news article: The Emerging Use of Bispecific Antibodies with Chemotherapy in Diffuse Large B-Cell Lymphoma To discuss the information in this episode with other oncology nurses, visit the ONS communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode “It was 2014 that most of us think of as the beginning of bispecifics in cancer, and that was with approval of blinatumomab. That was granted accelerated approval for the treatment of patients with Philadelphia chromosome–negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It is a bispecific that targets CD19-expressing tumor cells and CD3 on T cells. It's the original bispecific T-cell engager and is often called a ‘BiTE.'” TS 2:11 “The term ‘bispecific' means that this is an artificial protein that's developed to hit two different antigens simultaneously. They can be two different epitopes on the same antigen. They can be an antigen on a cancer cell and CD3 on a T cell that kind of recruits the T cell to the cancer. So, there are different types [of bispecific antibodies]. The subtype that we often talk about are bispecific T-cell engagers, which are those bispecifics that do target the T cell. And currently, the target on the T cell that's utilized is the CD3 molecule. That's not the only one that will be used in the future because there's a lot of work being done on other types of T-cell engagers.” TS 4:21 “The targets for lymphoma are CD20. Those are bispecific T-cell engagers that hit CD20 on the lymphoma cell, as well as CD3 on a T cell. ... In myeloma, we have two different targets that have been utilized. One is BCMA or B-cell maturation antigen. That sits on the surface of myeloma cells and on some healthy B cells. ... There's also a target used in myeloma that's called GPRC5D, which stands for G protein–coupled receptor, class C, group 5, member D. ... In small cell lung cancer, there's delta-like ligand 3 (DLL3); it's part of the NOTCH pathway. ... And then this year, we've had a couple agents come out that target HER2.” TS 6:52 “[Toxicities] are very dependent on what your target is. ... The bispecific T-cell engager that's used in myeloma that targets the GPRC5D is also expressed on tissues that produce hard keratin like hair follicles and actually, within the tongue. So the toxicities that we see with that agent are something you wouldn't expect to see if you were using a myeloma agent. You see nail and skin issues. You see taste problems. So it's very specific about the target, which says to me, that every time a new one of these agents comes out, I have to learn about the target that helps me learn about the toxicity. I find that fascinating and really appreciate that.” TS 16:19 “Cytokine release syndrome has been one of the areas that drug development has really focused on to see how they can help mitigate the severity [of it]. ... [One of] the strategies that has been incorporated and studied in clinical trials is the step-up dosing scheme. [It's] where you give initial small doses and over time, increase the dose to the dose you're going to continue with. Usually, monitoring in the hospital is required by the FDA approval for anywhere from 28–48 hours for the first couple of doses. And that's a real common strategy that you'll see. Premedication with H2 blockers, H1 blockers, sometimes steroids. These are also things that are incorporated within the approvals of these drugs and are important to look at.” TS 20:53

Die jongste oor die dood van SA se ambassadeur in Frankryk, Nathi Mthetwa. 'n Amerikaanse regeringsluiting tree in werking - 'n ekonoom verduidelik wat dit behels. Ons praat met die Wes-Kaapse premier, Alan Winde, oor sy sakebesoek aan die VSA.

In this episode, Simon reviews the latest property market data from September 2025. This podcast is produced in association with PaTMa (https://www.patma.co.uk/), the leading application for self managing landlords who want to save time and stay compliant. Easily track properties, tenancies, tenants, repairs, rent, mortgage payments and safety certificates. Get your FREE account today (https://www.patma.co.uk/). Episode links: * ONS report (https://www.ons.gov.uk/economy/inflationandpriceindices/bulletins/privaterentandhousepricesuk/september2025). * Get your free weekly property market stats from PaTMa (https://www.patma.co.uk/property-market-updates/). * Find us on YouTube (https://www.youtube.com/channel/UCRfrbvIJfodFK8tikisCjVw) or LinkedIn: Simon (https://www.linkedin.com/in/simonpither/). Subscribe to The Business of Property podcast on Spotify (https://open.spotify.com/show/73chI0Nqi9eRFUM7tkHc6r), Apple (https://podcasts.apple.com/gb/podcast/the-business-of-property/id1495635728), and all podcast platforms (https://www.thebusinessofproperty.com/subscribe). Please leave a rating and review if you're enjoying the show.

Send us a text2 Korintiërs 12:8,9 Drie maal het ek die Here gebid dat dit van my af weggeneem moet word. Sy antwoord was: “My genade is vir jou genoeg. My krag kom juis tot volle werking wanneer jy swak is.”. Hou jy daarvan om uitgedaag te word? So ‘n bietjie, solank dit my net nie ongemaklik laat voel nie. Ons gee nie om vir so 'n bietjie fisiese, intellektuele of emosionele uitdaging nie … solank dit ons nie onseker maak nie. Ek dink dis hoekom die meeste mense sommer vinnig die makliker uitweg kies.Ek het onlangs 'n interessante artikel van ‘n dame oor kognitiewe agteruitgang gelees. Die geleerde professor het gesê dat mense hier rondom sestig, 'n bietjie gemaklik raak. Hulle kan byvoorbeeld uitdagende en moeilike dinge vermy en op hul ervaring begin terugval. Dít, het sy gesê, is die ergste ding wat ons kan doen.Volgens haar, moet ‘n mens fokus op uitdagende aktiwiteite wat jou uitdaag en jou brein laat groei. Dis goeie raad, maar moenie nou agteruitsit en sê: Maar ek is nog nie 60 nie! Sy het ook gesê dat die mens se brein eintlik al op dertig begin krimp.So, hou jy daarvan om uitgedaag te word op 'n manier wat jou sal toets en selfs ongemak sal veroorsaak? Sommige atlete doen dit, maar die meeste mense is sku daarvoor. Ons is geneig om ‘n verskoning te soek en te sê, dit staan dan in die Bybel dat God getrou is en ons nie bo ons kragte sal versoek nie. Ons beskou sy liefde en trou as ‘n verskoning. Maar my vriend, dis nie reg nie. Dis die ergste ding wat ons kan doen.Paulus het homself met die spreekwoordelike doring in sy vlees bevind. 2 Korintiërs 12:9 Drie maal het ek die Here gebid dat dit van my af weggeneem moet word. Sy antwoord was: “My genade is vir jou genoeg. My krag kom juis tot volle werking wanneer jy swak is.”God sal ons nie meer verantwoordelikheid gee as wat ons kan hanteer nie. Hy help ons om te hanteer wat ons gegee word. Berei jouself voor om uitgedaag te word.Dis Sy Woord. Vars … vir jou … vandag. Support the showEnjoying The Content?For the price of a cup of coffee each month, you can enable Christianityworks to reach 10,000+ people with a message about the love of Jesus!DONATE R50 MONTHLY

Ruim een half jaar na hun stuntzege in Bergamo treft Club Brugge opnieuw Atalanta in de Champions League. Of het alweer even vlot loopt voor Nicky Hayen en co is nog maar de vraag, want beide ploegen ondergingen een metamorfose. Een goed resultaat voor blauw-zwart is wel wenselijk, want nadien volgen wedstrijden tegen Bayern, Barcelona en Arsenal. Voorts keert The Special One terug naar Chelsea en spelen drie Champions League-debutanten hun eerste thuiswedstrijd. Ons panel houdt nauwlettend de wedstrijd in het verre Kazachstan in de gaten. Daar ontvangt het nietige Kairat Almaty het grote Real Madrid. Was er ooit een grotere mismatch op het kampioenenbal? En we gooien bloemetjes naar KV Mechelen. Na negen speeldagen staat Malinwa netjes tussen Club Brugge en Anderlecht geparkeerd op de derde plaats. Hoewel de data ons leren dat de Maneblussers tot nu de grootste ‘overperformer' van de competitie zijn, leeft bij Evert wellicht al de hoop dat hij KV Mechelen eindelijk eens in Play-Off 1 kan zien aantreden.

Hoe heeft KEES KWAKMAN speelronde 7 beleefd? Je hoort het in deze aflevering van De Derde Helft. Amateurs Snijboon, Tim en Rogier aan tafel. Kees Kwakman is aangeschoven om ze eens te vertellen hoe het echt zit.✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delen waar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

Biologisch eten is in opkomst, maar in Nederland blijft de grote doorbraak nog steeds uit. Waarom lopen wij achter op een aantal andere landen in Europa?Deze aflevering in het kort:☑️ Nederlanders eten veel minder biologisch dan de rest van Europa☑️ Voor echte groei blijkt overheidsinkoop en steun voor boeren cruciaal.☑️ De impactpluim is voor Medewerkers van de toekomstBiologisch eten belooft veel: minder bestrijdingsmiddelen, meer biodiversiteit en een eerlijkere prijs voor de boer. Toch blijft de Nederlandse consument achter. Slechts 4,4 procent van ons eten is biologisch, terwijl landen als Oostenrijk al rond de 30 procent zitten. Hoe komt dat verschil? Dat vragen we aan Hendrik Wijnen van DO IT Organic. Nederlanders blijken erg prijsbewust en zien biologisch vaak als te duur. Maar dat beeld klopt niet helemaal meer, vertelt hij. Het prijsverschil met gangbare producten wordt kleiner en supermarkten als Lidl en Albert Heijn geven inmiddels flinke kortingen of zetten meer biologisch in het schap.

Ons kraanwater lijkt vanzelfsprekend, maar schijn bedriegt: de kwaliteit van onze rivieren, meren en sloten is op dit moment de slechtste van heel Europa. Gelukkig zijn we in Nederland enorm goed in water zuiveren, maar vervuiling maakt het een steeds grotere uitdaging. Hoe vervuilder dat water raakt, hoe moeilijker én duurder het wordt om er schoon drinkwater van te maken. Daarom zoeken wetenschappers, zoals Roos Goedhart van de TU Delft, naar slimme manieren en nieuwe oplossingen om ons water veilig te houden. Schrijf je in voor onze nieuwsbrief: https://universiteitvannederland.substack.com 00:00 Problemen door vies water 00:30 Drinkwaterbronnen in Nederland onder druk 01:10 Kaderrichtlijn Water en Europese regels 02:52 waar komt ons drinkwater vandaan? 03:14 problemen met grondwater 04:34 ook de economie wordt geraakt 05:30 drinkwatertekort 06:10 hoe water wordt gezuiverd 07:10 is brak water de oplossing? 08:20 zuinig omgaan met ons water Wl je meer weten over Kaderrichtlijn Water? Hier vind je informatie van Rijkswaterstaat en Unie van Waterschappen ► https://unievanwaterschappen.nl/waterkwaliteit/kaderrichtlijn-water-krw/ & https://www.rijkswaterstaat.nl/water/wetten-regels-en-vergunningen/overige-wetten/kaderrichtlijn-water Wil je meer weten over het onderzoek van Roos? Dat vind je hier ► https://www.tudelft.nl/en/techforimpact/safe-drinking-water-thanks-to-bacteria & https://www.tudelft.nl/2021/citg/oplossing-voor-ijzerafval-verduurzaamt-drinkwatersector En haar wetenschappelijke publicaties ► https://scholar.google.com/citations?view_op=list_works&hl=nl&hl=nl&user=gqT62DEAAAAJ&scilu=&scisig=ACUpqDcAAAAAaNKrpF7-mxskNe-8p4D3ApKwkiw&gmla=AH8HC4xbwL2y0mFudf_wQMAS5KYrdbubpkMgj348VdjSHlj1eoFcqb9zolvzV0fkCue9ETi1Q4f-xmDJkYmAn9Ehy18px7B8mxOdzc22whmI7H_bloRTxT4GXQ&sciund=13221067559175913137 See omnystudio.com/listener for privacy information.

Herlewing—'n Godgesentreerde Raamwerk vir Ware Menslike WelsynHERLEWING, VERNUWING, TRANSFORMASIE, VERANDERING, NUWE LEWE! Ons hoor gerugte en getuienisse van HERLEWING regoor die aarde, soos mense terugkeer na die Here toe!! Ons vervang die TEENWOORDIGHEID en INSPRAAK van die Heilige Gees so maklik met videogrepe, prentjies en inspirerende woorde hier en daar… terwyl Hy wag om ons TE VUL met Sy HEERLIKHEID! “Lord Whatever You're doingIn this seasonPlease Don't do it without medo it without me”Herlewing is nooit net 'n emosionele hoogtepunt of 'n kerkdiens wat langer aanhou nie. Dit is 'n kollektiewe openbaring—'n hele gemeenskap wat die erns van sonde erken, in berou terugkeer, en weer die ou paaie van toewyding aan God begin loop.Notas: www.harvestercederberg.co.za/herlewing-n-godgesentreerde-raamwerk-vir-ware-menslike-welsyn/Let us pray that He would find us WORTHY to impart His glory and grace as we empty ourselves to be filled with His Glory. #herlewing #vernuwing #nuwedinge #nuwelewe #ontwaking #transformasie #ingryping

Ons leer ken die prokureur wat haar toespits op geslagsgebaseerde geweld. September is doofheid-bewustheidsmaand. Die Bokke is slaggereed vir die Poemas in Durban.

“I think sometimes people don't expect pediatric patients to handle radiation as well as they do. They may have a family member who also had radiation for breast cancer or for prostate cancer and they were an older adult and had really severe side effects. And then they say, ‘Oh, no, I've got to put my little baby through this. I don't really want to do this.' We say kids are very different in how they handle this. They're very resilient, so we can provide good education about that,” Elizabeth Cummings, MSN, CPNP-AC, CPHON®, radiation oncology nurse practitioner at Children's Hospital of Philadelphia in Pennsylvania, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about radiation treatment care for pediatric patients. Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0   Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by September 26, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.  Learning outcome: Learner will report an increase in knowledge related to radiation oncology treatment care for pediatric patients. Episode Notes   Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 365: Radiation-Associated Secondary Cancers Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices Episode 298: Radiation Oncology: Nursing's Essential Roles Episode 204: How Radiation Is Used in Palliative Care Episode 50: Difficult Decisions in Childhood Cancer ONS Voice articles: Fertility Preservation Protects Possibilities for Patients With Cancer Have Meaningful Conversations With Pediatric, Adolescent, and Young Adult Patients and Their Families Pediatric Cancer Survivors Require Additional Care and Monitoring Prepare Survivors for the Risk of Secondary Cancers Secondary Cancers in Pediatric Survivors ONS book: Manual for Radiation Oncology Nursing Practice and Education (Fifth Edition) ONS courses: Essentials in Survivorship Care for the Advanced Practice Provider ONS/ONCC® Radiation Therapy Certificate™ Clinical Journal of Oncology Nursing articles: Radiation Therapy Survivorship: Healthcare Providers' Perspectives on Education and Care Radiation Therapy: Understanding the Patient Experience Reducing Pediatric Patient Anxiety: Implementing a Nonpharmacologic Intervention to Aid Patients Undergoing Radiation Therapy Other ONS Resources Inclusive Care Learning Library Late Effects of Cancer Treatment Huddle Card Proton Therapy Huddle Card Radiation Huddle Card Radiation Learning Library Oncolink Jr. Pediatric Radiation Oncology Society  To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode  “I think one of the things to think about with kids is sometimes they're not as forthcoming with what's going on, and sometimes it's a little bit harder to understand. Sometimes that's just because developmentally, they're much younger. A 1-year-old can't exactly tell you what's wrong. And so you're really trying to figure it out based on their cues versus a teenager who can tell you, but maybe they're too embarrassed about something in a way that an adult might not be.” TS 7:01 “Child life specialists are incredible. ... They provide age-appropriate education and explanations for patients, so talking to a 3-year-old about cancer is very different from an 8-year-old or even a teenager. They really are able to meet each patient exactly where they are and at the level that they are, and then provide the appropriate amount of information, which is so helpful for a patient since they learn to build trust and cope with their treatment and [they feel like they] have somebody who can relay that information in a clear and concise way.” TS 11:16 “There's certainly growing concern about the potential effects of anesthesia on brain health, especially in a vulnerable population like very young children, which are the ones who need anesthesia. We really try to mitigate this by optimizing our anesthetic agents, so we'll use propofol, which has a really quick onset and offset. And even when the radiation treatment is done, they'll stop the propofol in the radiation room—even though they are still walking back to recovery, just to minimize the amount of time that it's on—and trying to use the lowest dose possible. We also [explore] a lot of nonanesthetic strategies, [like] child life support, trying to introduce video distraction when we can, and having music and audiobooks.” TS 17:47 “[In] pediatrics, the patient, not the parent, is your patient. And that can look really different for a 3-year-old versus a 17-year-old. Somebody who can't officially sign consent, but they certainly have a lot of buy-in about the things that reach their body, versus a 3-year-old, where the parents are really taking ownership of that. I think sometimes it's tricky in the world of pediatrics as we think about the ethics of ‘Who are we training here? Is it the patients? Is it the parents?' And we continue to advocate for our patients.” TS 23:32 “I think that pediatric patients still want to be normal kids. They still want to do their normal activities. ... Our pediatric patients, a lot of times, have healthier tissues. They haven't seen as much wear and tear. They haven't developed the bad habits of some adults. They don't have the same environmental exposures, they're not smoking, they probably have fewer comorbidities. ... They're a different population. ... They're just amazing. They still want to be a kid, they still want to go to school, they still want to be with their friends. It's really encouraging to see that.” TS 36:03 

„We lopen rond met een stenen­tijdperk­brein in een digitale wereld,” zegt Mark van Vugt. Overal ziet hij de mismatch tussen ons oerbrein en de moderne samenleving. „Onder het dunne laagje beschaving blijft de oermens aanwezig.” Dat oerbrein verklaart ook onze liefde voor oorlog, legt hij uit. We streven naar vrede, maar juist dat zou ons volgens hem hartstikke depressief maken. „Ons brein is gevormd door heftige emoties en oorlog geeft daar voeding aan.”Diezelfde logica ziet hij terug in sport. „De evolutionaire geschiedenis van voetbal zit in de jacht.” Van Vugt voetbalde zelf, gaf psychologisch advies aan FC Southampton en coachte een team. Zijn onderzoek wees uit dat landen die hoger op de FIFA-ranglijst staan minder oorlog voeren: „Hoe meer er wordt gevoetbald, hoe minder er wordt gevochten.”Heeft u vragen, suggesties of ideeën over onze journalistiek? Mail dan naar podcast@nrc.nl.Presentatie: Pieter van der WielenRedactie en productie: Merel van Waalwijk van DoornMixage: AudiochefMuziek: Rufus van BaardwijkFoto: NRCZie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

President Ramaphosa sinspeel daarop dat Suid-Afrika gasheer kan speel vir vredesgesprekke tussen Oekraïne en Rusland. Ons praat met 'n psigiater oor die tekens van iemand wat selfdood beplan. Die Bokke pak die Poemas môre in Durban.

Hierdie week gaan ry Wiele2Wiele 'n draai met BMW se 118 en sy wilde boetie, die M235. BYD het sy splinternuwe Dolphin Surf  bekendgestel - tans die bekostigbaarste elektriese motor in Suid-Afrika.  Ons deel praktiese raad oor ‘run-flat'-bande en gesels oor die indrukwekkende BMW R 1300 GS Adventure-motorfiets. Wiele2Wiele op Facebook · Wiele2Wiele op Maroela Media

Send us a textPsalm 27:10 Selfs al sou my pa en ma my verlaat, die Here sal my styf vashou. (NLV) 'n Baie slegte ding wat met jou kan gebeur, is as iemand op wie jy staatmaak, jou in die steek laat. Daar is baie mense in hierdie wêreld wat deur hul ouers versaak is. Ons sien ook soms hoe baie intieme verhoudings verbreek word, waar die een party, op pad na groener weivelde, sy sielsgenoot weggooi. Om verwerp te word, is 'n verskriklike ding. Jy kan selfs omring wees deur mense wat oënskynlik goeie voornemens het en steeds heeltemal alleen voel.Josephine Bakhita is in 1869 in Soedan gebore. Sy is as kind ontvoer en as ‘n slaaf verkoop. Verlate en geskei van haar gesin, het sy geweldige lyding verduur. Sy is toe later op ‘n wonderbaarlike wyse, deur 'n goeie, godvresende familie gered.Dit is waar sy Christus ontmoet het en sy het die res van haar lewe daaraan gewy om ander te dien. Op een of ander manier het God haar pyn gedurende daardie traumatiese jare in ‘n kragtige getuienis van vergifnis, veerkragtigheid en onwrikbare geloof omskep.Psalm 27:10 Selfs al sou my pa en ma my verlaat, die Here sal my styf vashou. (NLV)Dawid het meer as 3 000 jaar gelede hierdie Psalm geskryf. Hy het, deur die lewensgevaarlike tye waarin hy baie gely het, eerstehands geweet dat God altyd daar sal wees vir hom.Dit is moeilik om enigiets meer desperaat of gevaarliks voor te stel as 'n kind wat deur sy ouers verlaat word. Tog, soos in Josephine se geval, het God die manier om sulke verskriklike omstandighede te neem en dit ten goede te laat uitwerk.Dit was soortgelyk aan die ervaring wat ek deurgemaak het toe my eerste vrou my meer as 30 jaar gelede vir 'n ander man verlaat het. En ek kan getuig, dat toe ek my in daardie verskriklike tyd tot God gewend het, het Hy wonderlike dinge gedoen – Hy doen steeds wonderwerke. Hy kan slegte dinge in goeie dinge verander.Selfs al verlaat ander mense jou; sal God jou altyd styf vashou.Dit is Sy Woord. Vars … vir jou … vandag.Support the showEnjoying The Content?For the price of a cup of coffee each month, you can enable Christianityworks to reach 10,000+ people with a message about the love of Jesus!DONATE R50 MONTHLY

“Ons almal weerspieël die heerlikheid van die Here, want die sluier is van ons gesig af weggeneem. Ons word al meer verander om aan die beeld van Christus gelyk te word. Die heerlikheid wat van ons uitstraal, neem steeds toe. Dit doen die Here wat die Gees is.” - 2 Korintiërs 3 Luister hier saam [...]

Op de start van Algemene Vergadering van de Verenigde Naties is er deze week één agendapunt dat domineert: de erkenning van de staat Palestina. Onder meer Frankrijk, het Verenigd Koninkrijk en Canada gaan over tot die erkenning. Ons land ook, maar onder voorwaarden. Netanyahu is furieus en zweert dat er nooit een Palestijnse staat zal zijn. Dreigt Israël het geweld nog verder te escaleren? Hoe belangrijk is die erkenning van Palestina? En zijn de Palestijnen nu geholpen met de erkenning van hun land? Journalisten Koen Vidal, Jorn De Cock | Presentatie en redactie Alexander Lippeveld | Redactie Jutte Verelst | Eindredactie Sofie Steenhaut | Audioproductie en muziek Brecht Plasschaert | Chef podcast Alexander Lippeveld See omnystudio.com/listener for privacy information.

Verschillen de hersenen van psychopaten veel van die van de gemiddelde mens? Waarom doen mensen kwaadaardige dingen? Ieder mens is in staat om kwaadaardige dingen te doen, maar de één heeft er minder moeite mee dan de ander. Hoe werkt dat in je hersenen? En wanneer is iets eigenlijk echt kwaadaardig? Leer van neurowetenschapper Inti Brazil en filosoof Marcel Becker en denk verder over kwaad, mededogen en verantwoordelijkheid. Ons brein en het kwaad | Lezing en gesprek met neurowetenschapper Inti Brazil en filosoof Marcel Becker | Woensdag 3 september 2025 | 20.00 – 21.30 uur | Collegezalencomplex, Radboud Universiteit | Radboud Reflects en Donders Instituut voor Neurowetenschappen. Lees het verslag: https://www.ru.nl/services/sport-cultuur-en-ontspanning/radboud-reflects/nieuws/ons-brein-en-het-kwaad-lezing-en-gesprek-met-neurowetenschapper-inti-brazil-en-filosoof-marcel-becker Bekijk de video: https://www.youtube.com/watch?v=rxS6MAMpGXo Bekijk ook de agenda voor nog meer verdiepende lezingen: www.ru.nl/radboudreflects Wil je geen enkele verdiepende lezing missen? Schrijf je dan in voor de nieuwsbrief: www.ru.nl/rr/nieuwsbrief

Elf lande erken nou 'n Palestynse staat, maar kan dit vrede in Gasa bewerkstellig? Internasionale Gebaretaaldag word vandag gevier. Ons praat met sanger Danie Botha wat verkondig dat die wegraping vandag en môre plaasvind.

In zijn biografie stelt Björn Borg zich open over zijn depressie, overdoses en agressieve vorm van kanker die hij ternauwernood overleefde…nadat dat de tennislegende 42 jaar in stilte heeft geleefd. We bespreken het boek met Borg's generatiegenoot en jeugdtegenstander Martin Bohm. De NL Tennis Podcast wordt gepresenteerd door Marcella Mesker en Jan-Willem de Lange. De titelmuziek is van Anthony Vega. De NL Tennis Podcast wordt onder meer verspreid via de nieuwsbrief van PassaTennis. Reageren op deze podcast? Je vindt ons op X: @NLTennisPodcast. Instagram: @nltennispodcast. Ons mailadres is nltennispodcast@gmail.com.

Hoe heeft PIETER ZWART super sunday beleefd? Je hoort het in deze aflevering van De Derde Helft. Voor speelronde 6 zitten de amateurs Snijboon, Tim en Gijs aan tafel. Pieter Zwart is aangeschoven om ze eens te vertellen hoe het echt zit. ✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delen waar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

Ons is gelowiges, kinders van die lewende God, mense met ʼn toekomsverwagting, op pad na ʼn ewigheid saam met Hom. Ons soek geleenthede op waar ons saam kan bely en aanbid.

Deze week gaan we in gesprek met een bijzondere gast, Stef Koenis. Hij weet als onderzoeker bij de Zuiderwaterlinie alles over de waterlinies in ons land. Het werd een prachtig gesprek waarin Stef historische context schetst en ons meeneemt in het fascinerende verhaal van de waterlinies in ons land.  

De ThermalPod is een batterij gevuld met gesmolten zout. Die zet duurzame energie om in hitte en kan zo fabrieken laten draaien, ook als de zon niet schijnt. Deze aflevering in het kort: ☑️ Hoe de ThermalPod werkt en waarom gesmolten zout nu wél door kan breken ☑️ De voordelen van warmteopslag voor fabrieken én het elektriciteitsnet ☑️ Een impactpuim voor het team van Carbyon Gesmolten zout als warmteopslag klinkt misschien futuristisch, maar de technologie bestaat al decennialang. Toch brak het tot nu toe niet op heel grote schaal door. Thomas Stroes is de oprichter van Saltes en legt uit dat dit te maken heeft met corrosieproblemen en hoge temperatuurvereisten. Deze uitdagingen heeft Saltes nu opgelost met een nieuw zoutmengsel en slimme materiaalkeuze. Het resultaat? Een systeem dat energie met een efficiëntie van 90 tot 95 procent opslaat en teruggeeft. Luister ook | CO2 onder de zeebodem: doorbraak of tijdelijke uitweg De voordelen zijn minder afhankelijkheid van gas, lagere piekbelasting op het elektriciteitsnet en meer ruimte voor hernieuwbare energie. Na een succesvolle pilot in Zuid-Afrika is Saltes nu klaar voor de marktintroductie. ‘Met terugverdientijden van vier tot zeven jaar kan de businesscase voor veel fabrieken interessant zijn', aldus Stroes. Hij verwacht dat deze technologie de komende jaren een belangrijke rol kan gaan spelen in het halen van de klimaatdoelen en het ontlasten van het volle elektriciteitsnet. Luister ook | Deze CO2-stofzuiger lost klimaatprobleem deels op Ons groene geweten Klaske Kruk deelt een impactpluim uit aan Hans de Neeve en zijn team van Carbyon. Zij presenteerden afgelopen week in Eindhoven de eerste demonstratie van hun Direct Air Capture-machine. Dat is een soort CO2-stofzuiger die historische uitstoot rechtstreeks uit de lucht haalt. Carbyon zegt dit sneller en efficiënter te kunnen doen dan wie dan ook wereldwijd. ‘En dat is precies de doorbraak die de wereld keihard nodig heeft', aldus Klaske.

“As ONS continues to look ahead, its commitment to shaping the future of oncology nursing remains unwavering. ONS is proactively developing the tools, capabilities, and strategies needed to support oncology nurses in a rapidly evolving healthcare landscape. ONS will continue to set the standard, ensuring that oncology nurses are equipped with clinical expertise, collaborative skills, technology proficiency, and mentorship necessary to thrive,” Diane Barber, PhD, APRN, ANP-BC, AOCNP®, FAANP, FAAN, member of the ONS 50th anniversary committee, said regarding the continuously changing roles of oncology nurses. Barber spoke with ONS members Danelle Johnston, MSN, RN, HON-ONN-CG, OCN®, RuthAnn Gordon, MSN, RN, FNP-BC, OCN®, Tamika Turner, DNP, NP-C, AOCNP®, and Bertie Fields, MS, RN, about their experience in nursing roles in navigation, clinical trials, advanced practice, and the pharmaceutical industry and how these roles have evolved and may change in the future. The advertising messages in this episode are paid for by Natera. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ episodes: ONS 50th anniversary series Episode 331: DNP and PhD Collaboration Strategies to Help Advance Oncology Care Episode 312: Virtual Nursing in Health Care Episode 304: Nursing Roles in FDA: The Drug Labeling and Package Insert Process Episode 302: Patient Navigation Eliminates Disparities in Cancer Care Episode 284: How AI Is Influencing Cancer Care and Oncology Nursing Episode 119: What Will the Future of Cancer Care Look Like in 2029? ONS Voice articles: Leadership Is the Foundational Competency for Oncology Nursing in 2029 New Technology Tools Help Oncology APRNs Improve Patient Outcomes Oncology Nurses Drive Discovery in Cancer Clinical Research The Oncology Nurse's Role in Interprofessional Collaboration in Clinical Research What the New CMS Reimbursement for Principal Illness Navigation Means for Oncology Nurses ONS books: Manual for Clinical Trials Nursing (third edition) Oncology Nurse Navigation: Delivering Patient-Centered Care Across the Continuum (third edition) ONS competencies: Oncology Clinical Nurse Specialist Competencies Oncology Clinical Research Nurse Competencies Oncology Nurse Generalist Competencies Oncology Nurse Navigator Competencies Oncology Nurse Practitioner Competencies ONS course: Professional Practice for the Advanced Practice Registered Nurse Clinical Journal of Oncology Nursing articles: How Do I Evolve as a Research Nurse Practitioner? Incorporating Nurse Navigation to Improve Cancer Survivorship Care Plan Delivery Oncology Nurse Practitioner Competencies: Defining Best Practices in the Oncology Setting ONS Learning Libraries: Clinical Trials Nurse Navigation Connie Henke Yarbro Oncology Nursing History Center American Cancer Society National Navigation Roundtable To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Johnston: “In the early years, navigation programs varied widely. We had minimal technology, no standardized training, and often tracked our work on spreadsheets and narrative notes. The broader healthcare team didn't always understand navigation, so educating colleagues in defining our role was essential. Today, navigation is becoming a well-established specialty. It's recognized by the Commission on Cancer, supported by [Centers for Medicare and Medicaid Services] reimbursement codes, and integrated across diverse care settings. It's backed by evidence, standardized training, and emerging technologies that improve both patient care and program sustainability. I'm proud to have witnessed and contributed to the incredible evolution, and I'm excited for what's next in advancing navigation to better support patients and families.” TS 6:20 Gordon: “When I was first introduced to the [clinical trial nurse] role, there weren't published competencies in order to learn the role or any real standardization of the role. And so when you worked in clinical trials, you kind of picked up things from the providers, from the other investigators on how you should operationalize the role. We've seen that evolve. We've seen ONS develop competencies, ONS come out with the clinical trial nursing manual. And our organization has been able to use those tools to standardize the practice of the clinical trial nurse across our institution. So we take those competencies, and they are the foundation of our program. And we've been able to build our program over the last decade, mostly by the use of the tools that ONS has and the ability to share knowledge.” TS 14:22 Fields: “For nurses, many of my colleagues are going on to get master's in things other than nursing. They're getting master's in public health. They're getting master's in business. I have a colleague who is in [information technology], and so we should not limit ourselves. We should expand ourselves. And the more varied degrees that we have, we are more viable candidates for positions. I was never a clinical nurse specialist, even though that was my goal, but I have done above and beyond what I ever anticipated that I would do. And there are so many more new degrees for us to make us viable in this changing environment.” TS 28:30 Turner: “It is vital that the current generation of oncology nurse practitioners take the lead to mentor the next generation. The next generation needs to be educated regarding the importance of oncology nurse practitioners, filling those critical gaps in health care by caring for patients in rural areas and those areas where healthcare resources are scarce. Technology should be utilized to bring oncology care—for example, office visits, imaging, and treatments—closer to those areas where patients live further away or have difficulty accessing transportation and health care. This will provide continuity of care.” TS 32:42

Dr. Tanya Thomas and Dr. Aparna Jotwani join the podcast to discuss the new Oncology Nursing Society and American Society of Clinical Oncology evidence-based guideline on the management of antineoplastic extravasation. They discuss recommendations from the expert panel on: management of extravasation of vesicant or irritant with vesicant properties antineoplastic agents, management of extravasation of paclitaxel or docetaxel, use & duration of thermal compress, and escalation of care. They share the importance of this comprehensive interdisciplinary guideline, highlight the algorithm as a useful tool for clinicians, and outline the outstanding questions related to the management of extravasation. Read the full guideline, “ONS/ASCO Guideline on the Management of Antineoplastic Extravasation” at www.asco.org/supportive-care-guidelines TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/supportive-care-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the JCO Oncology Practice, https://ascopubs.org/doi/10.1200/OP-25-00579  Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Tanya Thomas, clinical chair of the guideline and clinical nurse specialist from University of Virginia Health, and Dr. Aparna Jotwani, medical oncologist from Baylor College of Medicine, authors on "Management of Antineoplastic Extravasation: Oncology Nursing Society – American Society of Clinical Oncology Guideline." Thank you for being here today, Dr. Thomas and Dr. Jotwani. Dr. Aparna Jotwani: Thank you. Dr. Tanya Thomas: Thank you for having us. Brittany Harvey: And then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Thomas and Dr. Jotwani, who have joined us here today, are available online with the publication of the guideline in JCO Oncology Practice, which is linked in the show notes. So then to dive into the content here, Dr. Thomas, could you start us off by providing an overview of both the scope and the objectives of this guideline? Dr. Tanya Thomas: Yes, so the objective of this guideline is to provide the evidence-based recommendations to help support our interdisciplinary teams, including the oncologist, the advanced practice providers, pharmacists, and nurses who are involved in the care and management of patients who are experiencing an extravasation of an antineoplastic agent. While rare, the antineoplastic and certain chemotherapy extravasations are oncologic emergencies. The recommendations are to minimize negative consequences and provide a standardized approach to the care when such an event occurs. Dr. Aparna Jotwani: I would add that our scope is limited to intravenous antineoplastic vesicants, irritants, and irritants with vesicant potential. The scope of the guideline applies to the care team for adult oncology patients receiving treatments through venous access. Outside the scope is management of extravasation during other routes of treatment administration, such as intraperitoneal, intravesical, and hepatic arterial infusion. Our recommendations regarding vascular access for therapy or interventions to prevent extravasations are also outside of the scope for this guideline. Brittany Harvey: Understood. I appreciate that background and understanding what's in scope and what's out of scope for this guideline. So then I'd like to pivot and talk about the key recommendations of this guideline across the clinical questions. So first, Dr. Jotwani, what does the panel recommend for patients with extravasation of vesicant or irritant with vesicant properties antineoplastic agents? Dr. Aparna Jotwani: The panel strongly recommends for all classes where an antidote exists to proceed with using the antidote. Recommendations for paclitaxel and docetaxel are specifically addressed in a recommendation. This is further detailed in Tables 1 and 4 within the guideline. Evidence on the use of antidotes for extravasation is limited to nonrandomized, uncontrolled, observational studies and case series. Placebo-controlled trials on this topic would be unethical. There is also a lack of comparative data for different antidote strategies. However, potential benefits of using the antidotes include tissue preservation and avoiding tissue necrosis. In developing the guidelines, we had an in-person roundtable discussion and weighed risks and benefits to ensure patient safety above all else. Brittany Harvey: I appreciate that description of the recommendation here. So then you just mentioned that there's a specific recommendation for paclitaxel and docetaxel. So what is recommended for those patients with extravasation of paclitaxel or docetaxel? Dr. Aparna Jotwani: So here, we conditionally recommended the specific use of hyaluronidase as the antidote. This was based on five studies that all used hyaluronidase as an antidote to lower the risk of tissue necrosis. In the studies included, with a subgroup of patients that experienced taxane-related extravasation, development of necrosis ranged from 0% to 0.83% among the patients who received an antidote. The potential harms associated with this were likely trivial. Brittany Harvey: Thank you for providing that recommendation as well. So then the next section of the guideline, Dr. Thomas, what does the expert panel recommend for use and duration of thermal compress? Dr. Tanya Thomas: So the expert panel actually recommends the use of thermal compresses, and the recommendations are based on the available literature for the various agents and the actual time frames most frequently used for the compress application. The utilization of a thermal compress is recommended for 15 to 20 minutes at a time for 3 to 4 times daily, at least for the first 48 to 72 hours after that extravasation occurs. The actual frequency and duration may vary based on the extent of the extravasation and the agent involved in that extravasation. The intent of the warm compress is to help disperse the agent and reduce the localized accumulation of the agent, whereas the cold compress, it actually helps prevent the dispersion or the spread of the agent while allowing the antidote to help neutralize that agent. Warm compresses are recommended for extravasations involving the vinca alkaloids, etoposide, oxaliplatin, and the taxanes - paclitaxel and docetaxel - only when coadministering the antidote hyaluronidase. The use of a cold compress is actually recommended for extravasations involving the anthracyclines, antimetabolites, alkylating agents, and taxanes when coadministration of the antidote hyaluronidase does not occur. Brittany Harvey: Understood. Those specific and actionable recommendations are really key for clinical practice. So then, following those recommendations, how does the guideline address escalation of care and surgical referral for patients with central line extravasation? Dr. Tanya Thomas: So this topic actually had a lot of discussion. And while there is not enough evidence to make strong recommendations, the expert panel recognized that surgical referrals should be considered in certain scenarios. Dr. Aparna Jotwani: We discussed that certain scenarios would include high-risk populations, such as patients that are receiving DNA-binding vesicants, those with high-volume estimated extravasation, and those with CTCAE grade 2, which would be erythema associated with symptoms such as edema, pain, induration, and phlebitis, or grade 3, which would be symptoms of ulceration or necrosis or concern for severe tissue damage, or grade 4, where you would have a life-threatening consequence extravasation, may have a greater likelihood of benefiting from surgical referral and/or escalation of care as deemed appropriate. Brittany Harvey: Great. And yes, it's really important to provide all of these recommendations that you've both just gone through, even when we're faced with very low evidence. So then, Dr. Thomas, in your view, what is the importance of this guideline, and how will it impact clinical practice? Dr. Tanya Thomas: So when extravasations occur in the clinical setting, members of the interdisciplinary team can be faced with barriers related to where to look for the information, how to find all the relevant information in one concise place, how to provide education to the patient about how to care for the site of extravasation in the home setting, and also when to escalate to specialized teams. This can actually cause some added stress and anxiety, and in certain circumstances, may lead to delays in efficient management. This guideline provides the resource clinicians have been looking for. It includes comprehensive recommendations for antineoplastic extravasations in one guideline while also providing a one-page algorithm with the key information regarding the management of the extravasations. This allows all levels of providers to have evidence-based recommendations regarding initial management of the extravasation, for instance, how to manage the infusion, key site assessment reminders, available antidotes, and the use of thermal compress; the required documentation, recommended follow-up scheduling, in addition to key aspects of the patient education. This type of guidance is not found in any other single document regarding antineoplastic extravasation. Having this document readily available at the point of care potentially can reduce time required for providers to search for management recommendations and also provide consistency in patient education and follow-up management scheduling. It reduces uncertainty within interdisciplinary teams and can help inform policy development for clinicians to approach extravasations with confidence. Brittany Harvey: Absolutely. I agree that this is an incredible resource for clinicians with the recommendations, the algorithm that you mentioned, and the supporting evidence that underpins these recommendations to really provide both efficient and effective care for patients. So beyond the impact for clinical practice, Dr. Jotwani, how will these guideline recommendations affect patients receiving antineoplastic treatment for cancer? Dr. Aparna Jotwani: Exactly. In addition to the clinical care team, we want to help and benefit our patients. So, oncology patients that experience extravasations are at risk for, aside of the side effects of tissue necrosis and infection, they also are at risk for delay of cancer treatment. In making these guidelines, we kept in mind the cost and the efforts for patients, additional visits that they could incur, additional time and supplies for care of the extravasation, as well as cost. Our guideline aims to provide an evidence-based approach to the care of oncology patients receiving antineoplastic intravenous therapy. While there are gaps in the data due to the nature of these events, based on careful literature review, these guidelines serve as a basis for quality, standardized oncology care during extravasation. Personally, I hope our graphics especially can be used across the systems to guide clinical care. Brittany Harvey: Definitely. We hope that these recommendations improve treatment and treatment outcomes for all patients receiving antineoplastic treatment for cancer. So then you've also just mentioned some gaps in the literature. So Dr. Thomas, I'd like to turn to you to wrap us up and ask, what are the outstanding questions for the management of antineoplastic extravasation? Dr. Tanya Thomas: Yes, that's a good question. Two of the main outstanding questions are related to the management of extravasations involving the novel agents and extravasations involving multi-agent regimens. The current literature regarding how to effectively manage the multi-agent regimens, for instance, there is no clear guidance for managing the extravasation for someone who is receiving a regimen that involves simultaneous administration of, let's say, a vinca alkaloid and an anthracycline. One of those agents requires a warm compress while the other requires a cold compress, and there are different antidotes for those two agents. Additionally, there has not been a lot of published information on the impact of extravasation of those novel agents like the antibody-drug conjugates. With the pace of the drug development, a subgroup of the guideline panelists actually are exploring case reports specific to novel agents to help inform some future work. Brittany Harvey: Yes, we'll look forward to learning more about how to address these ongoing issues and potentially impact guideline recommendations in the future as well. So I want to thank you both so much for your work to develop this incredibly important guideline, and thank you for your time today, Dr. Thomas and Dr. Jotwani. Dr. Aparna Jotwani: Thank you for the opportunity. Dr. Tanya Thomas: Yes, thank you. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/supportive-care-guidelines. I also encourage you to check out the companion episode on this guideline on the ONS podcast, available on Amazon Music, Apple Podcasts, Spotify, and YouTube Music. And finally, you can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you've enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Die geskorste Minister van Polisie word betrek by 'n Gautengse misdaadsindikaat. Ons praat met 'n politieke ontleder oor gister se plofbare getuienis voor die Madlanga-kommissie. Navorsing wys dat die Regering van Nasionale Eenheid se beloftes min vordering toon. Die Openbare Beskermer versoek om adjunkpresident Paul Mashatile se seuns te ondersoek.heid se beloftes min vordering toon. Die Openbare Beskermer versoek om adjunkpresident Paul Mashatile se seuns te ondersoek.

Food and drink prices are rising at their fastest rate since January last year, whilst the overall headline rate of inflation remains unchanged at 3.8 per cent. Food prices are expected to peak in December as hot weather has led to a poor harvest and higher industry costs. According to ONS figures, the biggest price rises in food and drink include beef and veal, butter, coffee, chocolate and milk. Martin Lines, CEO of the Nature Friendly Farming Network, and an arable farmer in Cambridgeshire, joins us to discuss how the current challenges mean consumers are paying more for everyday essentials. And in part two, The Standard's Chief Theatre Critic, and host of The London Theatre Review podcast, Nick Curtis, joins us to discuss his five star review of The Producers musical at the Garrick Theatre. Hosted on Acast. See acast.com/privacy for more information.

Ons praat met 'n voormalige Wes-Kaapse polisiekommissaris oor die voortslepende massaskietery op die Kaapse Vlakte. 'n Kenner ontleed die ANC se diensleweringsomkeerplan. Inflasieverwagtinge is op sy laagste vlak ooit, maar beteken dit 'n rentekoersverlaging?

Welkom terug bij De Derde Helft. Ook dit seizoen zijn jullie nog niet van ons af. Integendeel. Je kunt ons meer, vaker, langer en op meer verschillende kanalen volgen (en wellicht bewonderen) dan ooit. In deze podcast aflevering schuift FREEK JANSEN aan tafel bij SNIJBOON, GIJS en TIM om speelronde 05 te bespreken! ✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delen waar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

Wat is zonde?Zonde is waanzin. Het is het middel waarmee de denkgeest tot waanzin wordt gedreven en probeert illusies de plaats te laten innemen van de waarheid. En in zijn waanzin ziet hij illusies waar de waarheid hoort te zijn, en waar die in werkelijkheid ook is. Zonde heeft het lichaam ogen gegeven, want wat is er dat de zondelozen zouden willen zien? Welke behoefte hebben zij aan beelden of geluiden of aanrakingen? Wat zouden ze willen horen of waar zouden ze naar willen grijpen? Wat zouden ze überhaupt zintuiglijk willen waarnemen? Zintuiglijk waarnemen is niet kennen. En de waarheid kan alleen met kennis zijn gevuld, en met niets anders.Het lichaam is het instrument dat de denkgeest gemaakt heeft in zijn pogingen zichzelf te misleiden. Zijn doel is te streven. Maar het doel waarnaar het streeft kan veranderen. En nu dient het lichaam een ander streefdoel. Waar het nu op uit is wordt bepaald door het doel dat de denkgeest zich heeft gesteld ter vervanging van zijn doel van zelfmisleiding. Waarheid kan evengoed als leugens zijn doel zijn. In dat geval zullen de zintuigen zoeken naar getuigen van wat waar is.Zonde is de bakermat van alle illusies, die slechts staan voor denkbeeldige zaken voortkomend uit gedachten die onwaar zijn. Ze zijn het ‘bewijs' dat wat geen werkelijkheid heeft, toch werkelijk is. Zonde ‘bewijst' dat Gods Zoon slecht is, dat aan tijdloosheid een eind moet komen, en dat eeuwig leven sterven moet. En God Zelf heeft de Zoon verloren die Hij liefheeft, waarbij Hem niets rest dan verval om Hem compleet te maken, Zijn Wil voor eeuwig door de dood overwonnen is, liefde is vermoord door haat, en vrede niet langer bestaat.De dromen van een gek zijn angstaanjagend, en zonde lijkt inderdaad angst aan te jagen. En toch is wat de zonde ziet slechts een kinderspel. De Zoon van God kan spelen dat hij een lichaam werd, ten prooi aan het kwaad en aan schuld, met maar een kortstondig leven dat eindigt in de dood. Maar al die tijd straalt zijn Vaders licht over hem en heeft Hij hem met een eeuwigdurende Liefde lief, waaraan zijn pretenties in het geheel niets kunnen afdoen.Hoelang, o Zoon van God, wil je nog doorgaan met het spel van de zonde? Zullen we dit scherpgekante kinderspeelgoed niet eens afdanken? Hoe snel ben je bereid naar huis te komen? Vandaag misschien? Er is geen zonde. De schepping is onveranderd. Wil jij je terugkeer naar de Hemel nog steeds tegenhouden? Hoelang nog, o heilige Zoon van God, hoelang?LES 258Laat ik me herinneren dat God mijn doel is.Al wat nodig is, is onze denkgeest erin te trainen voorbij te zien aan alle futiele, zinloze doelen en ons te herinneren dat God ons doel is. De herinnering van Hem ligt verscholen in onze denkgeest, slechts verduisterd door onze kleine nutteloze doelen die niets te bieden hebben en niet bestaan. Blijven we toestaan dat Gods genade in onbewustheid straalt, terwijl we in plaats daarvan de speeltjes en prulletjes van de wereld zoeken? God is ons enig doel, onze enige Liefde. We hebben geen ander streven dan ons Hem te herinneren.Ons doel is niets anders dan de weg te volgen die leidt naar U. We hebben geen ander doel. Wat zouden we anders kunnen verlangen dan ons U te herinneren? Wat zouden we anders kunnen zoeken dan onze Identiteit?Alle tekst- werk en handboek klassen van Een Cursus in Wonderen met Elbert nu te beluisteren en te bekijken op https://decursusmetelbert.nl

Jesus het na 40 dae van vas en versoeking in die woestyn teruggekeer, in die krag van die Gees. Sy eerste stop? Sy eie tuisdorp, Nasaret. Daar het hulle Hom eers bewonder vir die “genadevolle woorde” uit sy mond… maar 'n oomblik later wou hulle Hom van die krans afgooi (Luk. 4:14–31).

  “One powerful, overlooked aspect of colorectal cancer survivorship is the emotional and identity transformation that our survivors undergo—and really how little space is given in the clinical arena for that. No one really talks about this ‘invisible recovery.' Facing mortality can lead to prolonged changes is values, relationships, and life goals. And these experiences aren't captured in lab results or imaging scans, but they really shape how survivors live, love, and heal and continue with their lives,” ONS member Kris Mathey, DNP, APRN-CNP, AOCNP®, gastrointestinal medical oncology nurse practitioner at The James Cancer Hospital of The Ohio State University Wexner Medical Center in Columbus, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about colorectal cancer survivorship. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by September 12, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase is knowledge related to colorectal cancer survivorship nursing considerations. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 374: Colorectal Cancer Treatment Considerations for Nurses Episode 370: Colorectal Cancer Screening, Early Detection, and Disparities Episode 201: Which Survivorship Care Model Is Right for Your Patient? Episode 153: Metastatic Colorectal Cancer Has More Treatment Options Than Ever Before ONS Voice articles: Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) Here Are the Current Nutrition and Physical Activity Recommendations for Cancer Survivors ONS course: Essentials in Survivorship Care for the Advanced Practice Provider Clinical Journal of Oncology Nursing article: Closing the Gaps: Addressing the Unmet Needs of Cancer Survivors Oncology Nursing Forum articles: Symptom Occurrence, Frequency, and Severity During Acute Colorectal Cancer Survivorship The Relationship Between Colorectal Cancer Survivors' Positive Psychology, Symptom Characteristics, and Prior Trauma During Acute Cancer Survivorship ONS Survivorship Care Plan Huddle Card ONS Learning Libraries: Colorectal cancer Survivorship Academy of Oncology Nurse and Patient Navigators American Cancer Society National Colorectal Cancer Roundtable Colorectal Cancer Alliance Colorectal Cancer Resource and Action Network Fight Colorectal Cancer Resource Library Livestrong at the YMCA Pan Ohio Hope Ride To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “As of the most recent data, more than 1.5 million people in the United States are living as colorectal cancer survivors. So this includes not only those who are currently undergoing active cancer treatment but also those who have completed treatment and ultimately are hopefully in remission. Just a reminder that colon cancer is the third most commonly diagnosed cancer in the United States and it's the fourth leading cause of cancer-related deaths.” TS 1:53 “Our colorectal cancer survivors may have significant barriers when receiving this comprehensive survivorship care, and these challenges can affect not only their physical recovery but their emotional well-being and, ultimately, their long-term health outcomes. We as oncology nurses do play a pivotal role in identifying and addressing these barriers. So these can include fragmented care. Who's caring for these patients? That care coordination between the oncologist and the oncology team and then the primary care providers and team. Limited access—so our patients that may have geographic limited access or also financial- or insurance-related obstacles to follow-up services.” TS 9:10 “Our nurses can also facilitate the communication between specialists and primary care providers, so making sure that we're sending records, keeping those lines of communications open. Also, nurses can provide that psychosocial support, so our screening for distress and also advocating and supporting for referral to counseling or support groups for a patient. Nurses can also act as navigators to guide these patients through complex care systems.” TS 11:21 “Some of the recommended changes—nutrition—enhancing and emphasizing fruits, vegetables, that colorful plate, with whole grains. Limit those red and processed meats, and reduce sugary drinks and alcohol. I know we will all have those patients who have read things or cancer myths about, ‘Oh, cancer feeds on sugar, so I shouldn't drink anything or eat anything with sugar,' and maybe addressing that, just really emphasizing the well-rounded meals.” TS 19:57 “When we think about [ourselves], ‘Well, I don't have an implicit bias,' but we may not think about what that is. Some common preconceived assumptions are that survivorship equals a cure. And this assumption may overlook that chronic symptoms or those late effects and emotional needs of long-term survivors. So knowing that when a patient is coming to us on surveillance, they may be cured; they may not have active cancer, but they're still dealing with some of those chronic symptoms—and acknowledging that.” TS 30:37 “There's an assumption that an ostomy equals poor quality of life, and this may stigmatize patients and discourage open conversations about adaptation and support. A couple weeks ago, I volunteered at the Pan Ohio Hope Ride, which is with the American Cancer Society, and several states have a ride that's similar. And there was a patient riding, and I could tell over his jersey that he had an ostomy bag underneath that. And I just looked at him and I thought, ‘That's amazing. You are still functioning, still living, still riding a bike throughout the entire state of Ohio with an ostomy.' So he's still having that good quality of life. That doesn't stop him from living.” TS 31:39

Elke paar dekades word ons gebless met 'n prinses.In dié geval 'n pop-prinses! Not a pop — ek is nie 'n seksistiese vark nie; vrouens is nie poppe of poplappe nie. Hulle is prinsesse! Dís die enigste aanvaarbare P-woord. Goeiste, moenie my hier vandag opgewerk maak nie!Ons is gelukkig genoeg om die pop-prinses van Afrikaanse musiek vandag hier by ons te hê!Sy drip van talent... not to be confused with Demi Moore.To partner with PRAATING, visit www.praating.com Podcast en video production The Media Farm

“All of these TKIs [tyrosine kinase inhibitors] inhibit BCR-ABL1 in some way, shape, or form. When BCR-ABL1 is mutated, it has uncontrolled tyrosine kinase activity, leading to rapid cell proliferation. When we then inhibit that BCR-ABL1 that's been mutated, we disrupt this abnormal signaling pathway that drives CML [chronic myeloid leukemia] cell proliferation and survival, ultimately leading to decreased cancer cell growth, increased apoptosis or cell death, and potentially inducing a disease remission,” Samantha Maples, PharmD, BCOP, clinical pharmacy specialist supervisor for hematology and cellular therapy at Allegheny Health Network in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the BCR-ABL1 inhibitor drug class.   Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0   Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by September 5, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.  Learning outcome: Learner will report an increase in knowledge related to the use of BCR-ABL1 inhibitors in the treatment of CML. Episode Notes   Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 322: Nursing Strategies to Reduce Readmission Rates for Patients With Cancer Episode 215: Navigate Updates in Oral Adherence to Cancer Therapies ONS Voice articles: Adherence to Oral Anticancer Medication Combination Therapy Shows Promise for Chronic Myeloid Leukemia The Case of the Medication Modification The Case of the Safety Session ONS course: Safe Handling Basics Clinical Journal of Oncology Nursing articles: Targeted Drug Therapies: Beyond Blood Counts and Chemistries Oncology Nursing Forum articles: Adherence and Coping Strategies in Outpatients With Chronic Myeloid Leukemia Receiving Oral Tyrosine Kinase Inhibitors Fear of Progression in Outpatients With Chronic Myeloid Leukemia on Oral Tyrosine Kinase Inhibitors Other ONS resources: Biomarker Database Financial Toxicity Huddle Card Tyrosine Kinase Inhibitors Huddle Card Oral Anticancer Medication Care Compass: Resources for Interprofessional Navigation Oral Anticancer Medication Learning Library National Comprehensive Cancer Network National Comprehensive Cancer Network patient resources To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode  “The IRIS study led to the approval of the BCR-ABL1 and TKI, imatinib, for CML in 2001 and completely changed the landscape of CML treatment. Then came the second-generation BCR-ABL1 TKIs: dasatinib in 2006, quickly followed by nilotinib in 2007. Thereafter came our second-generation, bosutinib, and our first approved third-generation TKI, ponatinib, both in 2012, which was a huge milestone as ponatinib overcomes resistance to the T315 I mutation, which no previously approved TKIs worked against.” TS 2:16 “The newest approved TKI, asciminib, is an allosteric inhibitor that binds to a different pocket on the BCR-ABL kinase via allosteric binding to the ABL myristoyl pocket. It's what's called a STAMP inhibitor, where STAMP stands for ‘specifically targeting the ABL myristoyl pocket.' And while all the TKIs target the BCR-ABL1 binding site, they can also inhibit different off-target kinases. And these differences in off-target inhibition are responsible for some of the different toxicities we see among the TKIs.” TS 4:51 “As a class, common toxicities include nausea; vomiting; diarrhea; cardiac toxicities, including cardiac arrhythmias and congestive heart failure; metabolic abnormalities such as hypercholesterolemia and hypertriglyceridemia; nephrotoxicity; hepatic toxicity; hemorrhaging and bleeding; as well as cytopenia. Individually, some of these agents are more likely to cause certain side effects compared to others, and there are unique toxicities associated with certain TKIs.” TS 8:10 “We've moved to using preemptive loperamide [in our clinic] for the first three days of starting treatment, because it's really hard to get patients to continue to take a medication if they have such severe diarrhea that they end up in the hospital or they're unable to leave their house. A lot of times, we will proactively give patients antiemetics and loperamide to help with the nausea, vomiting, and diarrhea. And then we can back off to an as-needed basis once they've been established on treatment. We can also use medications to help manage long-term complications that can require supportive care, such as statin therapy for high cholesterol, levothyroxine for hypothyroidism, anticoagulants for any venous thromboembolism, and antihypertensive medications for managing any new or worsening high blood pressure.” TS 12:44 “We are continually seeing these agents expand their indications to different lines of therapy, as well as more TKIs being approved for acute lymphoblastic leukemia. For example, asciminib just got approved in the frontline setting within the last year, whereas previously it was only approved in relapsed refractory setting. Last year, imatinib was the first BCR-ABL1 TKI to come out with a commercially supplied suspension option as well, which is huge in the pediatric space and [for] our adult patients who are unable to swallow tablets for other clinical reasons.” TS 21:22 “There is more information being published on the safe discontinuation of these medications with treatment-free remissions, and more information is coming out about who would be eligible and who can have the option to stop these treatments instead of having a lifelong chronic condition requiring continuous treatment. We're seeing more patients in clinical practice be able to stop BCR-ABL1 treatment, which has been a great development in CML.” TS 25:29

Die parlement win 'n regsmening in oor of die ontbinde SA Toerismeraad heraangestel moet word. 'n Dringende ondersoek gevra na vuurwapengeweld op die Kaapse Vlakte. 16 Organisasies is as vriende van die hof toegelaat in 'n saak oor die dekriminalisering van sekswerk. Ons vind uit hoe die Madlanga-kommissie met voorbereidings vorder vir sy eerste sitting.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! FDA Accepts Priority Review Application of Omidubicel for Severe Aplastic Anemia  The FDA accepted a priority review application for omidubicel, a cell therapy under investigation for severe aplastic anemia. FDA Approves REMS Label Update for Sparsentan (Filspari) in IgA Nephropathy  The FDA approved an updated REMS label for sparsentan, easing monitoring requirements for patients with IgA nephropathy. FDA Issues CRL to Outlook Therapeutics' ONS-5010 for the Treatment of Wet AMD The FDA issued a complete response letter for ONS-5010 in wet AMD, citing insufficient efficacy evidence from the phase 3 program. ACC Releases Respiratory Disease Vaccination Guidelines for Adults with Heart Disease The ACC released new guidance recommending vaccination against respiratory infections for adults with cardiovascular disease to improve prevention and access. Orforglipron Delivers Weight Loss, A1C Reductions in Phase 3 ATTAIN-2 Trial Eli Lilly reported phase 3 results showing orforglipron improved weight and glycemic control in adults with obesity or overweight and type 2 diabetes.

Palantir is een bedrijf dat weinig mensen kennen, maar een steeds grotere impact heeft. Ze ontwerpen onder meer tools die met AI oorlogsdoelwitten bepalen. “Ons product doodt soms mensen”, verkondigt ceo Alex Karp regelmatig. Wat voor een bedrijf is Palantir? En is het progressief-libertaire Silicon Valley veranderd in een Trumpgezinde oorlogsindustrie? Journalist Ruud Goossens | Presentatie en eindredactie Alexander Lippeveld | Redactie Sofie Steenhaut | Audioproductie en muziek Brecht Plasschaert | Chef podcast Alexander Lippeveld See omnystudio.com/listener for privacy information.

Welkom terug bij De Derde Helft. Ook dit seizoen zijn jullie nog niet van ons af. Integendeel. Je kunt ons meer, vaker, langer en op meer verschillende kanalen volgen (en wellicht bewonderen) dan ooit. In deze podcast aflevering schuift TOINE VAN PEPERSTRATEN aan tafel bij PEPIJN, GIJS en TIM om speelronde 04 te bespreken! ✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delen waar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

“She's triple negative and has a very, very aggressive tumor. Instead of going on spring break that year, she sat in our chemo room and got chemo. Her friends from college are good to try to keep her involved and try to surround her and encourage her, but they're right now in very, very different spots in their lives. She's fighting for her life; her friends are fighting for the grade they get in a class—and that's different,” ONS member Kristi Orbaugh, MSN, NP, AOCN®, AOCNP®, nurse practitioner at Community Hospital North Cancer Center in Indianapolis, IN, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about metastatic breast cancer in adolescent and young adult patients. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  This podcast is sponsored by Lilly and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Episode Notes This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 368: Best Practices for Challenging Patient Conversations in Metastatic Breast Cancer Episode 354: Breast Cancer Survivorship Considerations for Nurses Episode 350: Breast Cancer Treatment Considerations for Nurses Episode 345: Breast Cancer Screening, Detection, and Disparities Episode 307: AYAs With Cancer: Financial Toxicity Episode 300: AYAs With Cancer: End-of-Life Care Planning ONS Voice articles: ‘Cancer Ghosting' May Add Another Layer of Emotional Burden for Patients Discoveries in Race-Related Breast Cancer Biomarkers May Improve Precision Treatments What Is HER-2-Low Breast Cancer? What Oncology Nurses Need to Know About Supporting AYAs With Cancer ONS books: Guide to Breast Cancer for Oncology Nurses Oncology Nursing Forum articles: An Integrative Review of the Role of Nurses in Fertility Preservation for Adolescents and Young Adults With Cancer Impact of Race and Area Deprivation on Triple-Negative Metastatic Breast Cancer Outcomes Relations of Mindfulness and Illness Acceptance With Psychosocial Functioning in Patients With Metastatic Breast Cancer and Caregivers ONS huddle cards: Altered Body Image Fertility Preservation Sexuality Other ONS resources: Breast Cancer Learning Library Fertility Preservation in Individuals With Cancer ONS Biomarker Database American Cancer Society's breast cancer resources American Society of Clinical Oncology continuing education resources Elephants and Tea Life, Interrupted Livestrong National Cancer Institute's breast cancer resources Stupid Cancer Young Survival Coalition To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “When we use ‘adolescent and young adult,' we're really talking about age 19–35. Some groups will say 15–39, but right around that age. When we think about that age, think about what all could be going on during those ages. Late teenagers, they may be going off to college, they may be graduating high school, trying to set up their own life, trying to become independent from mom and dad. If you're talking about early to mid 30s, you could be talking about young parents, young career folks. So, just setting that into place makes you realize this can be a very tumultuous time for folks.” TS 2:06 “Unfortunately, this group tends to have more aggressive subtypes. We see more triple-negative in this group. We see more hormone-negative, HER2-positive in this group. Normal breast cancer cells should be stimulated by hormone. They are stimulated by hormones. So when you have a breast cancer cell that is not driven by hormones, it's much more difficult to treat. We tend to see more aggressiveness in these tumors. We also see a higher incidence in non-Caucasian folks in this age group compared to the older age groups.” TS 4:53 “I think we have gotten much better about understanding the importance of fertility preservation and getting reproductive endocrinologists in, sooner rather than later. If we have earlier-stage cancers and we have patients that want to try to preserve eggs, preserve fertility, sperm banking. … If you have that time to talk to them—maybe a 21-year-old—the primary thing on her mind is not how many children she wants to have one day. Maybe she's not even thought about having kids yet. It's still a question you need to [ask]. Do you want to try to preserve fertility? Do you want to try to harvest some eggs? That's a conversation that needs to be had and is very, very important for that age group.” TS 10:35 “One thing that helps is if you can get them [into] reputable support groups with people their own age that are going through what they're going through. Someone else that doesn't have hair, someone else that isn't going to make it to the big board meeting or isn't going to get the promotion this year because they've had to take a medical leave. Someone else that understands it differently.” TS 16:47 “In breast cancer, many of those biomarkers just get reflexed. And what I mean by reflexed is a breast cancer pathology comes through, or a breast cancer specimen comes through, and it just automatically gets tested for X, Y, Z. HER2 and of course ER/PR. Now we understand that we don't just need to know whether they're HER2 positive or HER2 negative. We need to know: What is the IHC score? And even if the IHC score is zero, is there any membrane staining? And then we need to know what's their ESR1, their PTEN, their AKT, their PIK3CA. Those are so important to know.” TS 18:11 “I think it's important to try to remember what our priorities were when we were in our 20s—what our priorities were when we were starting out as young mothers or starting out our career. Because that's where these folks are. … I can't imagine in the midst of college, when I'm trying to be independent, to suddenly have to be at home and rely on my mom to take me to my chemo appointment. … So I think one really important bias is to remember where they are in the developmental stages of life. They're not 40-something. They haven't lived X amount of life, and we need to take a step back and try to remember when we were their age, what was important to us? Where were our priorities at that point? And then hear them when they're telling us what's important to them.” TS 29:22 “From a female standpoint … we frequently throw these patients into menopause or have early menopausal symptoms, and I think we forget how devastating that can be. … They now are at higher risk for osteopenia or osteoporosis. … And then we tell people, ‘Be as normal as possible, get back and do those normal things.' Well, they're in a relationship, and they want to be intimate [but] suddenly having sexual intercourse is incredibly painful. Or if it's not painful, sometimes they've just lost pure interest in that. They don't feel confident about their body. All of those things need to be addressed because patients are trying to live each day as normally as possible.” TS 31:55 

Welkom terug bij De Derde Helft. Ook dit seizoen zijn jullie nog niet van ons af. Integendeel. Je kunt ons meer, vaker, langer en op meer verschillende kanalen volgen (en wellicht bewonderen) dan ooit. In deze podcast aflevering schuift NOA VAHLE aan tafel bij PEPIJN, GIJS en ROGIERPABLO om speelronde 03 te bespreken! ✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delen waar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

“Policies help make sure that we're giving patients the right education and discharge instructions. Radiation doesn't end when the syringe is empty. Patients go home with potential radioactive exposure. They need to know how to protect their families, what precautions to take, and what healthcare providers can do if something goes wrong—like a spill, extravasation, or even a pregnant staff member who's involved in the care. This isn't just a documentation exercise. It's about making sure every part of the system speaks the same language when it comes to safety, handling, and patient care,” ONS member Ella-Mae Shupe, MSN, RN, OCN®, nursing practice and professional development specialist for radiation oncology at Johns Hopkins Health System Sydney Kimmel Cancer Center based in Baltimore, MD, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about creating and implementing radiopharmaceutical policies and procedures.  Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0   Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 22, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.  Learning outcome: Learner will report an increase in knowledge related to implementing policies and procedures to support administration of radiopharmaceuticals for cancer treatment. Episode Notes   Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 347: Care Considerations for Radiopharmaceuticals and Theranostics in Patients With Cancer Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices Episode 298: Radiation Oncology: Nursing's Essential Roles Episode 104: How Radiation Affects All Areas of Oncology Nursing ONS Voice articles: New Radiopharmaceutical Improves Survival in Advanced Prostate Cancer Radiopharmaceuticals and Theranostics Offer New Options for Oncology Nurses to Transform Cancer Care Radiopharmaceuticals Pack a One-Two Punch Against Cancer Safety Is Key in Use of Radiopharmaceuticals ONS Voice oncology drug reference sheets: Lutetium Lu 177 Dotatate Lutetium Lu 177 Vipivotide Tetraxetan Radium 223 Dichloride Sodium Iodide-131 ONS book: Manual for Radiation Oncology Nursing Practice and Education (Fifth Edition) ONS course: ONS/ONCC® Radiation Therapy Certificate™ Clinical Journal of Oncology Nursing article: Nursing Telemedicine Educational Encounters: Improved Patient Satisfaction in Radiation Therapy Clinics Other ONS resources: ONS Radiation Learning Library ONS Radiation Safety: In the Home Huddle Card ONS Radiopharmaceuticals Huddle Card Daily Med Lutathera® website for healthcare professionals Pluvicto® website for healthcare professionals Xofigo® website for healthcare professionals To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode  “[Lutetium lu 177 vipivotide tetraxetan] has shown so effective in clinical studies that the FDA recently approved expanded use, and it can now be given prior to chemotherapy.” TS 1:56 “There are typically three parts to a radiopharmaceutical. One is a radioisotope, which emits the radiation. The second is a targeting molecule, which directs the compound to a specific site. And the third is a linker that binds the isotope to the targeting molecules securely. The targeting molecule is usually a substance that binds specifically to receptors, antigens, or metabolic pathways that are overexpressed on cancer cells.” TS 2:08  “We have an interdisciplinary team involvement. There's a physicist, nurse, and provider that confirm lab values are within normal limits. The patient meets all the clinical and safety criteria for administration. Second is an IV placement where a nurse or clin tech starts the IV and verifies a strong blood return. This is critical to avoid extravasation, which can be harmful due to the vesicant-like nature of radiopharmaceuticals. And third, our patient voids immediately before the injection, which reduces bladder radiation dose. During the administration, our provider administers the radiopharmaceutical using a shielded syringe holder to reduce radiation exposure. The physicist remains present throughout the procedure. Lead aprons are worn by any team members close to the IV site, and then the Geiger counter is used by physics to measure ionizing radiation, which is done before, during, and after the procedure.” TS 3:28 “The policy we created doesn't just address general principles. It includes very specific guidance for both [radium 223 dichloride] and [lutetium lu 177 vipivotide tetraxetan]. That includes everything from determining patient eligibility to completing the treatment directive, confirming patient identity, verifying delivery parameters, documenting the treatment itself, and ensuring the treatment environment is appropriate and safe. We've also built in drug- specific practices because [radium 223 dichloride] and [lutetium lu 177 vipivotide tetraxetan] each come with their own considerations. This includes competencies for nursing, tailored patient education for each therapy, and an extravasation checklist that outlines what to do and who's responsible for tasks if infiltration occurs.”TS 11:24 “We created two separate versions [of an attestation model], one for clinical staff and one for non-clinical staff. Why include non-clinical staff? Because the risks extend beyond just the clinical team. What if environmental services comes in to clean and the patient has urinated on the floor? Or what if dietary delivers a tray and moves a urinal without knowing the risk? Or what if transport comes in and handles an incontinent brief without awareness? Each of these scenarios has potential for contamination and exposure. And that's exactly why education for all roles matter.” TS 15:22 “These are such an exciting treatment for our patients, that's not chemotherapy, that's not radiation, and their quality of life has been amazing. We have had patients coming in that could barely walk because of the pain from bone mets and after a few treatments, they're much better. We've had PSAs go from five, six hundreds down to 0.5, so we're seeing a lot of really good options for these patients and treatment.” TS 22:09  

What happens when a cybersecurity engineer walks into a fashion boutique? For Harish Chandramowli, it sparked an idea that's now helping small fashion brands save time, money, and sanity. A chance observation in a New York store became a mission to untangle problems in inventory, communication, and operations many brands struggle with. In this episode, I speak with Harish, founder of Flair Software, about how he went from working at Bloomberg and MongoDB to building a platform that fixes the messy back-office problems fashion brands face. Harish explains why seasonal inventory is a high-stakes game, how communication breakdowns can cost thousands, and why he built his solution to integrate with Shopify instead of competing against it. Tune in now to learn more. --- Listen to the podcast here: From Cybersecurity to Fashion Tech with Harish Chandramowli Welcome to Action's Antidotes, your antidote to the mindset that keeps you settling for less. We have a lot of technological advances, a lot of digital technology, and a lot of the efforts around it have been used primarily around digital products, primarily around some of the platforms and everything else, but there's also an aspect that I'm hopeful around that really takes some of the digital technology that we have and uses it to enhance the physical products and the actual life that we have outside of our computers in real life. My guest today, Harish Chandramowli, is the founder of Flaire Software and he has some interesting solutions for the fashion industry and other kind of inventory-related pursuits. ---   Harish, welcome to the program.   It's a pleasure to be here.    Thank you for joining us. Now, first of all, kind of have your feet in both worlds, whether it be kind of our technological world as well as the world of fashion, the world of some of these in-real-life types of pursuits. Tell me a bit about your story, where you started and how you came up with the idea, what you observed that led to Flaire Software.   Yeah. Just taking a step back, I am not from fashion industry. It's all pretty new to me. I did my master's in cyber security actually in Johns Hopkins, then I worked as security engineer in a bunch of very data-related platforms like Bloomberg, MongoDB. And MongoDB was my last gig where I primarily started as cloud security engineer but moved on to like an Atlas dedicated team where you see how lot of different people use databases. And, interestingly, there are a lot of retail companies using databases very heavily. That made me more and more curious on how software is being used in retail industry and why database is like one of the biggest line expenditures. On top of that, when I was looking into ERPs, Oracle is one of the biggest player in the ERP market, which made me even more curious on what this space is. What happens around here? Why is a database company spending so much on an ERP, on like a data workflow?    Yeah.   This kind of made me curious but, again, it was more like I don't think I was into fashion or any of those things. I went to this store called ONS in Soho. It's a great store you should check out if you are ever in like downtown area in New York.    What's the store called again?   ONS.   Okay.   Orange, Naples, San Diego. So if you go to Soho and like downtown in the fashion districts, you will notice a lot of these small, small brands which is not your typical H&Ms or Zara.   Yeah.    So I was there, I was actually listening to their team meetings, talking a lot with their founder. I was looking at how they are operating in the back office. The first thing that stood out to me is that fashion as a whole uses a lot of software. One aspect of it which we are all familiar with is designing the fashion, like the threading, modeling and like the cut and everything. Another easier to relate option is like e-commerce site, where you list,

Ukrainian President Volodymyr Zelenskyy and his European allies have met with Donald Trump for a charm offensive. Plus: Massive anti-war protests rock Israel, the ONS declares average rents in England to be unaffordable, and author Sally Rooney has been reported to the police over her support for Palestine Action. With Aaron Bastani and Tadhg Hickey.

Welkom terug bij De Derde Helft. Ook dit seizoen zijn jullie nog niet van ons af. Integendeel. Je kunt ons meer, vaker, langer en op meer verschillende kanalen volgen (en wellicht bewonderen) dan ooit. In deze podcast aflevering schuift THOMAS HOGELING aan tafel bij PEPIJN, GIJS en SNIJBOON om speelronde-02 te bespreken! ✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delenwaar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

“At least some of the answer to these issues of compassion fatigue and burnout have to do making our practice environments the very, very best they can be so that nurses and other clinicians can really connect and care for patients in the ways that they want to be able to do that—and the patients need them to be able to do. I think there's a lot that is here already and will be coming, and I feel pretty optimistic about it,” ONS member Anne Gross, PhD, RN, NEA-BC, FAAN, senior vice president for patient care services and chief nursing officer at Dana-Farber Cancer Institute in Boston, MA, told ONS member Christine Ladd, MSN, RN, OCN®, NE-BC, member of the ONS 50th anniversary committee, during a conversation about burnout and compassion fatigue in oncology nursing. Ladd spoke with Gross and ONS member Tracy Gosselin, PhD, RN, NEA-BC, AOCN®, FAAN, senior vice president and chief nursing executive at Memorial Sloan Kettering Cancer Center in New York, NY, about the history of nurse well-being and how nurses and health systems are approaching it today. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD.  ONS Podcast™ episodes: ONS 50th anniversary series Episode 315: Processing Grief as an Oncology Nurse Episode 292: What We Need to Do to Retain Today's Oncology Nursing Workforce Episode 291: Build a Sense of Belonging for Nurses and Patients Episode 264: Stop the Stressors and Improve Your Mental Health as a Nurse Episode 246: Create a Culture of Safety: Fair and Just Culture Episode 160: Build Innovative Staff Education Tools and Resources ONS Voice articles: Critical Event Debriefings Can Reduce Oncology Nurses' Risk of Compassion Fatigue and Burnout ONS Chapters and DNP Candidates Combine Forces to Support Oncology Nurse Well-Being Step Out of Reality With Virtual Breaks to Support Your Wellness at Work Clinical Journal of Oncology Nursing articles: Burnout and Well-Being: Evaluating Perceptions in Bone Marrow Transplantation Nurses Using a Mindfulness Application Engaging Nurse Residents Through Poetry Strategies to Mitigate Moral Distress in Oncology Nursing ONS Nurse Well-Being Learning Library ONS Communities ONS Chapters Connie Henke Yarbro Oncology Nursing History Center Oncology Nursing Foundation Resiliency Resources To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Gross: “I was on an oncology unit early in practice. And just like today, we were dealing with very sick patients. We were dealing with death and dying. We were administering very toxic treatments and really pushing a field forward in oncology. So there were similar challenges, but I think different from today. There weren't the kind of resources; there wasn't the body of work that's been done today around compassion fatigue and burnout, work-life balance, and things like that. There was not that body of literature and science like there is today. And so there was more of a grassroots kind of support building in the clinical environment that I think I experienced.” TS 2:35 Gosselin: “I think there's also a piece when we think about nurses in the work we do—we also have families. We have aging parents and children. And sometimes that burnout is multifactorial in that we have family obligations and other obligations that make it really hard. And for some people, they say work is their escape from some of that. Yet it's all hard to balance sometimes.” TS 8:09 Gosselin: “It's this question that people like Anne, myself, other chief nurses are saying. If we add this new technology, what are we going to take away? Do we need another alarm to ring to the phone or to their badge? How much can you ask people to do and not be distracted when they're at point of care delivering patient care? Technology should never be a distractor, nor should it tell us how to practice. The technologies we have today—I'm like, ‘Wow, I wish I had that when I started my career.' And yet there's also a double-edged sword to that. I think we have to balance when we think about care and care delivery.” TS 16:36 Gross: “There are so many resources, first of all, that ONS provides to all of us at all levels and in all points in our career and our path from novice to experts. And the needs, though, are the same. Whether you're a novice nurse or whether you're a very experienced nurse, you need to continue to learn and to get new information, and ONS is an incredible resource for that. … As I think both of us keep alluding to and emphasizing here, you also need that connection to other people. And that's what ONS provides—that opportunity to get connected to other people that might be working in some other part of the country or other part of the world but is dealing with similar things that you're dealing with. So it provides that opportunity, and then it also provides an opportunity to get involved. I think when you can get involved and be part of solving a problem, it doesn't then control you and you won't feel defeated by it.” TS 22:24

ONS ditches the recording studio again for Safe Summer Nights at West Minnehaha Recreation Center. Connecting with Mayor Carter, SPPD Chief Henry, and a host of partners and community for feedback! Check out more great episodes at f2fpodcastnetwork.comAlso, check the F2F Podcast Network on YouTube

“We're really using these in many, many types of malignancies. But you can see this class of drug, these monoclonal antibodies, the small molecule inhibitors, being used in colorectal cancer, ovarian cancer, renal cell carcinoma, brain cancers, hepatocellular, non-small cell lung cancer, gynecologic malignancies, so lots of different types of cancers where we're seeing these drugs used,” Danielle Roman, PharmD, BCOP, manager of clinical pharmacy services at the Allegheny Health Network Cancer Institute in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the vascular endothelial growth factor (VEGF) inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 8, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the use of VEGF inhibitors in the treatment of cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 303: Cancer Symptom Management Basics: Ocular Toxicities Episode 244: Cancer Symptom Management Basics: Cardiovascular Complications Episode 196: Oncologic Emergencies 101: Bleeding and Thrombosis Episode 161: Administer Bevacizumab Infusions With Confidence ONS Voice articles: Manage Afatinib's Adverse Events to Keep Patients on Treatment Oncology Drug Reference Sheet: Cabozantinib Oncology Drug Reference Sheet: Fruquintinib Patient Education Needs With Pazopanib Therapy for Soft Tissue Sarcoma ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) ONS courses: Safe Handling Basics Clinical Journal of Oncology Nursing article: Safety and Adverse Event Management of VEGFR-TKIs in Patients With Metastatic Renal Cell Carcinoma Oral Anticancer Medication Care Compass: Resources for Interprofessional Navigation ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit IV Cancer Treatment Education Sheets Oral Chemotherapy Education Sheets To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Cancer cells are known to secrete factors that cause the formation of new blood vessels, and tumors need blood vessels to supply themselves with nutrients so that they can grow and metastasize. A lot of tumors overexpress these factors, so they had more of this ability to create new blood vessels. You may hear that term somewhere neo vascularization. … And also these factors can increase the permeability of blood vessels, so making them kind of leaky blood vessels. … So the thought behind it is being able to block the ability for this new blood vessel formation and to decrease that leakiness or permeability of those blood vessels.” TS 2:07 “These are drugs that are tyrosine kinase inhibitors. These are oral, small molecule drugs that are acting intracellular, so they are working within the cell to bind and prevent that downstream signaling of producing more blood vessels. So we have a number of small molecule drugs that fall into this class. Many of them target multiple types of receptors, VEGF being included, but also a lot of these drugs have other targets.” TS 7:58 “I would really say, number one, something that we very commonly see with this drug class is hypertension. Giving you an example of bevacizumab—If we look at any grade hypertension, this can be up to 67% of patients, so very common toxicity really spanning all of these agents. So something that we need to be monitoring closely for.” TS 13:24 “With that impaired wound healing, keeping that in mind, as we are planning for this agent, for patients and even sometimes with the minor surgical procedures, maybe a need for a short hold, and even for something like a catheter placement. I know and some of the providers I work with have a preference for holding for a short period of time around that as well.” TS 20:15 “I think one big area, and we've seen some of this just recently, and particularly in the hepatocellular setting, we're seeing combinations of using the VEGF inhibitor class with immunotherapy. And so I think we're going to continue to see that evolve. Even hearing about some bispecific antibodies that are in development, where they are targeting VEGF as well as PD-L1, so getting the immunotherapy and VEGF effects.” TS 24:44

“Colorectal cancer treatment is not just about eliminating a disease. It's about preserving life quality and empowering patients through every phase. So I think nurses are really at the forefront that we can do that in the oncology nursing space. So from early detection to survivorship, the journey is deeply personal. Precision medicine, compassionate care, and informed decision-making are reshaping outcomes. Treatment's just not about protocols. It's about people,” ONS member Kris Mathey, DNP, APRN-CNP, AOCNP®, gastrointestinal medical oncology nurse practitioner at The James Cancer Hospital of The Ohio State University Wexner Medical Center in Columbus, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about colorectal cancer treatment.  Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 1.0 contact hour of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 1, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the treatment of colorectal cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 370: Colorectal Cancer Screening, Early Detection, and Disparities Episode 153: Metastatic Colorectal Cancer Has More Treatment Options Than Ever Before ONS Voice articles: Colorectal Cancer Prevention, Screening, Treatment, and Survivorship Recommendations Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) How Liquid Biopsies Are Used in Cancer Treatment Selection Oncology Drug Reference Sheet: 5-Fluorouracil Oncology Drug Reference Sheet: Oxaliplatin What Is a Liquid Biopsy? Clinical Journal of Oncology Nursing article: Colorectal Cancer in Young Adults: Considerations for Oncology Nurses Oncology Nursing Forum article: Neurotoxic Side Effects Early in the Oxaliplatin Treatment Period in Patients With Colorectal Cancer ONS Colorectal Cancer Learning Library ONS Biomarker Database (filtered by colorectal cancer) ONS Peripheral Neuropathy Symptom Interventions American Cancer Society colorectal cancer resources CancerCare Colorectal Cancer Alliance Colorectal Cancer Resource and Action Network Fight Colorectal Cancer National Comprehensive Cancer Network To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Colorectal cancer has several different types, but there is one that dominates the landscape, and that is adenocarcinoma. So I think most of us have heard that. It's fairly common, and it accounts for about 95% of all colorectal cancers. It begins in the glandular cells lining the colon or rectum and often develops from polyps, in particular adenomatous polyps.” TS 1:41 “One of the biomarkers that we'll most commonly hear about is KRAS or NRAS mutations. This indicates tumor genetics, and these mutations suggest resistance to our EGFR inhibitors such as cetuximab. BRAF mutation or V600E is a more aggressive tumor subtype, and those may respond to our BRAF targeted therapy. … And then our MSI-high or MMR-deficient—microsatellite instability or mismatch repair deficiency—that really predicts an immunotherapy response and may indicate Lynch syndrome, which is a huge genetic component that takes a whole other level of counseling and genetic testing with our patients as well.” TS 6:02 “Polypectomy or a local excision—that removes our small tumors or polyps during that colonoscopy. And that's what's used for those stage 0 or early stage I cancers. A colectomy removes part or all of the colon. This may be open or laparoscopic. It can include a hemicolectomy, a segmental resection, or a total colectomy, so where you take out the entire part of the colon. A proctectomy removes part or all of the rectum. This may include a low anterior resection, also known as an LAR … or an abdominal perineal resection, which is an APR. … Colostomy or ileostomy—that diverts the stool to an external bag via stoma. Sometimes this is temporary or permanent depending on the type of surgery.” TS 14:11 “We'll have our patients say, ‘Hey, I want immunotherapy therapy. I see commercials on it that it works so well.' We have to make sure that these patients are good candidates for it, also that we're treating them adequately. We need to make sure that they have those biomarkers, so as I mentioned, the MSI-high or MMR tumors. Our MSS-stable tumors—they may benefit from newer combinations or clinical trials. Metastatic disease—immunotherapy may be used alone or with other treatments. And then in the neoadjuvant setting, some trials are really showing promising results using immunotherapy prior to surgery.” TS 25:38 “Antibody-drug conjugates are really an exciting frontier in all cancer treatments as well as colorectal cancer treatment. This is used mainly for patients with advanced or treatment-resistant disease, and these therapies combine the targeted power of monoclonal antibodies with the cell-killing ability of potent chemotherapy agents. They're still on the horizon for the most part in colorectal cancer. However, there is only one approved antibody-drug conjugate, or ADC, at this time, and that's trastuzumab deruxtecan, or Enhertu. That's approved for any solid tumor, such as colorectal cancer with HER2 IHC 3+. So again, looking back at that pathology in those markers, making sure that you have that HER2 mutation and that IHC.” TS 35:00 “There are a few myths going around about colorectal cancer treatment that can lead to confusion or even delayed care. One myth is only older men get colorectal cancer. As you heard me talk in my previous podcast on screening, unfortunately, this isn't necessarily true. Colorectal cancer affects both men and women and our cases in the younger population are rising. So our screening guidelines have changed to age 45 because we are seeing it in the younger population.” TS 45:54